Pavella Therapeutics Inc. (PVLA)
Market Closed
2 Mar, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
132. 61
-2.41
-1.78%
$
1.6B Market Cap
- P/E Ratio
- Div Yield
366,889 Volume
- Eps
$ 135.02
Previous Close Day Range
130.8 141.59
Year Range
18.23 151.18
Want to track PVLA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
PVLA earnings report is expected in 27 days (30 Mar 2026)
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst
Palvella Therapeutics offers a compelling risk/reward profile, underpinned by strong Phase 2 data and a pivotal Phase 3 catalyst in Q1 2026. Palvella's QTORIN rapamycin platform demonstrates high local efficacy with minimal systemic exposure, validated across multiple rare skin disease indications. With $63.6M in cash and a recent $80M raise, Palvella is well-capitalized to reach key data readouts and NDA preparation, minimizing financing risk.
Seekingalpha | 2 months ago
